Copyright
©The Author(s) 2024.
World J Stem Cells. Feb 26, 2024; 16(2): 70-88
Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.70
Published online Feb 26, 2024. doi: 10.4252/wjsc.v16.i2.70
No | Trial ID | UC-MSCs administration protocol | Phase | Status | Patients | Age (yr) | Follow-up time | Mask | Allocation | Country | ||
Frequency | Dose (cells) | Route | ||||||||||
1 | NCT04293692 | 4 (at days 1, 3, 5 and 7) | 0.5 × 106/kg | IV | N/A | Withdrawn | 48 | 18-75 | N/A | Triple-blind | Randomized | China |
2 | NCT05682586 | 2 (at days 1 and 4) | 1 × 106/kg | IV | III | Recruiting | 60 | 18-75 | N/A | Open-label | Randomized | China |
3 | NCT05501418 | 1 | N/A | IV | I/II | Active, not recruiting | 75 | 20-80 | 12 months | Single-blind | Randomized | China |
4 | NCT05719012 | 3 (at months 1, 2, and 3) | N/A | IV | II | Not yet recruiting | 70 | 18-80 | 96 wk | Triple-blind | Randomized | China |
5 | NCT04273646 | 4 (at days 1, 3, 5 and 7) | 0.5 × 106/kg | IV | N/A | Unknown | 48 | 18-65 | 96 wk | Open-label | Randomized | China |
6 | NCT05689008 | 2 (at days 1 and 4) | 1 × 106/kg | IV | III | Recruiting | 60 | 18-85 | N/A | Open-label | Randomized | China |
7 | NCT04457609 | 1 | 1 × 106/kg | IV | I | Unknown | 40 | 18-95 | N/A | Triple-blind | Randomized | Indonesia |
8 | NCT05132972 | 3 (at days 0, 3, and 6) | 1 × 106/kg | IV | II/III | Recruiting | 42 | 18-75 | 90 d | Quadruple-blind | Randomized | Indonesia |
9 | NCT04288102 | 3 (at days 0, 3, and 6) | 4.0 × 107 | IV | II | Completed | 100 | 18-75 | 90 d | Quadruple-blind | Randomized | China |
10 | NCT04366271 | 1 | N/A | N/A | II | Withdrawn | 100 | 40-80 | N/A | Open-label | Randomized | Spain |
11 | NCT04371601 | 4 (once every 4 d) | 1 × 106/kg | IV | I | Unknown | 60 | 18-70 | N/A | Open-label | Randomized | China |
12 | NCT04429763 | 1 | 1 × 106/kg | N/A | II | Unknown | 30 | 18-79 | N/A | Triple-blind | Randomized | United States |
13 | NCT04461925 | 3 (at days 1,4 and 7) | 1 × 106/kg | IV | I/II | Unknown | 30 | 18-75 | N/A | Open-label | Non-Randomized | Ukraine |
14 | NCT04269525 | 4 (at days 1, 3, 5 and 7) | 3.3 × 107 | IV | II | Unknown | 16 | 18-80 | N/A | Open-label | N/A | China |
15 | NCT04437823 | 3 (at days 1, 3, and 5) | 0.5 × 106/kg | IV | II | Unknown | 20 | 30-70 | N/A | Open-label | Randomized | Pakistan |
16 | NCT04573270 | 1 | N/A | IV | I | Completed | 40 | 18 to older | N/A | Triple-blind | Randomized | United States |
17 | NCT05286255 | 2 (at days 1 and 4) | 1.25-1.5 × 106/kg | IV | I | Not yet recruiting | 10 | 18-80 | N/A | Open-label | N/A | United States |
- Citation: Meng M, Zhang WW, Chen SF, Wang DR, Zhou CH. Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects. World J Stem Cells 2024; 16(2): 70-88
- URL: https://www.wjgnet.com/1948-0210/full/v16/i2/70.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i2.70